Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 5, Pages 787-794Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw030
Keywords
phosphoproteomics; sarcoma; signal transduction; clinical trials; drug resistance
Categories
Funding
- Institute of Cancer Research
- Cancer Research UK [C36478/A19281]
- Sarcoma UK [003.2014]
- Liddy Shriver Sarcoma Initiative
- Cancer Research UK [19281] Funding Source: researchfish
Ask authors/readers for more resources
This review discusses the role of phosphoproteomics as a tool for translational cancer research. We provide an overview of current phosphoproteomic technologies and highlight their advantages and limitations. We then use sarcoma as an illustrative example to demonstrate how phosphoproteomics may be deployed for target discovery, biomarker development and combination therapy.Phosphoproteomics has been extensively used as a preclinical research tool to characterize the phosphorylated components of the cancer proteome. Advances in the field have yielded insights into new drug targets, mechanisms of disease progression and drug resistance, and biomarker discovery. However, application of this technology to clinical research has been challenging because of practical issues relating to specimen integrity and tumour heterogeneity. Beyond these limitations, phosphoproteomics has the potential to play a pivotal role in translational studies and contribute to advances in different tumour groups, including rare disease sites like sarcoma. In this review, we propose that deploying phosphoproteomic technologies in translational research may facilitate the identification of better defined predictive biomarkers for patient stratification, inform drug selection in umbrella trials and identify new combinations to overcome drug resistance. We provide an overview of current phosphoproteomic technologies, such as affinity-based assays and mass spectrometry-based approaches, and discuss their advantages and limitations. We use sarcoma as an example to illustrate the current challenges in evaluating targeted kinase therapies in clinical trials. We then highlight useful lessons from preclinical studies in sarcoma biology to demonstrate how phosphoproteomics may address some of these challenges. Finally, we conclude by offering a perspective and list the key measures required to translate and benchmark a largely preclinical technology into a useful tool for translational research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available